Market Cap
AU$80.5m
Last Updated
2020/06/06 10:35 UTC
Data Sources
Company Financials +
Executive Summary
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products.
Rewards
Risk Analysis
Snowflake Analysis
Excellent balance sheet with high growth potential.
Share Price & News
How has Immutep's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: IMM's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-10.8%
IMM
3.2%
AU Biotechs
4.0%
AU Market
1 Year Return
-36.5%
IMM
40.7%
AU Biotechs
-7.0%
AU Market
Return vs Industry: IMM underperformed the Australian Biotechs industry which returned 41.5% over the past year.
Return vs Market: IMM underperformed the Australian Market which returned -6.9% over the past year.
Shareholder returns
| IMM | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.8% | 3.2% | 4.0% |
| 30 Day | 22.2% | -6.2% | 12.2% |
| 90 Day | -53.5% | -8.0% | -2.5% |
| 1 Year | -36.1%-36.5% | 42.2%40.7% | -3.1%-7.0% |
| 3 Year | -46.4%-46.8% | 117.7%110.3% | 19.0%3.3% |
| 5 Year | -80.7%-80.8% | 220.4%200.5% | 33.9%5.0% |
Price Volatility Vs. Market
How volatile is Immutep's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 day ago | Simply Wall St
Could The Immutep Limited (ASX:IMM) Ownership Structure Tell Us Something Useful?3 weeks ago | Simply Wall St
The Immutep (ASX:IMM) Share Price Is Down 84% So Some Shareholders Are Rather Upset1 month ago | Simply Wall St
Is Immutep Limited's (ASX:IMM) CEO Salary Justified?Valuation
Is Immutep undervalued compared to its fair value and its price relative to the market?
2.29x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate IMM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate IMM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: IMM is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: IMM is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate IMM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: IMM is good value based on its PB Ratio (2.3x) compared to the AU Biotechs industry average (3x).
Next Steps
Future Growth
How is Immutep forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
71.2%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: IMM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.3%).
Earnings vs Market: IMM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: IMM's is expected to become profitable in the next 3 years.
Revenue vs Market: IMM's revenue (25.7% per year) is forecast to grow faster than the Australian market (4.2% per year).
High Growth Revenue: IMM's revenue (25.7% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if IMM's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Immutep performed over the past 5 years?
27.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: IMM is currently unprofitable.
Growing Profit Margin: IMM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: IMM is unprofitable, but has reduced losses over the past 5 years at a rate of 27% per year.
Accelerating Growth: Unable to compare IMM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IMM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.6%).
Return on Equity
High ROE: IMM has a negative Return on Equity (-55.71%), as it is currently unprofitable.
Next Steps
Financial Health
How is Immutep's financial position?
Financial Position Analysis
Short Term Liabilities: IMM's short term assets (A$26.9M) exceed its short term liabilities (A$4.0M).
Long Term Liabilities: IMM's short term assets (A$26.9M) exceed its long term liabilities (A$11.0M).
Debt to Equity History and Analysis
Debt Level: IMM's debt to equity ratio (29.3%) is considered satisfactory.
Reducing Debt: IMM's debt to equity ratio has increased from 15.1% to 29.3% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: IMM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: IMM has sufficient cash runway for 1.2 years if free cash flow continues to grow at historical rates of 1.1% each year.
Next Steps
Dividend
What is Immutep's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate IMM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate IMM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if IMM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if IMM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of IMM's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
4.0yrs
Average management tenure
CEO
Marc Voigt (46yo)
5.92yrs
Tenure
AU$836,828
Compensation
Mr. Marc Voigt has been the Chief Executive Officer of Immutep Limited (formerly, Prima BioMed Ltd) since July 9, 2014. Mr. Voigt has been the Chief Financial Officer and Chief Operating Officer at caprote ...
CEO Compensation Analysis
Compensation vs Market: Marc's total compensation ($USD581.13K) is above average for companies of similar size in the Australian market ($USD259.62K).
Compensation vs Earnings: Marc's compensation has been consistent with company performance over the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 5.92yrs | AU$836.83k | 1.57% A$1.3m | |
| COO, General Counsel & Company Secretary | 3.58yrs | AU$484.74k | 0.51% A$414.2k | |
| Chief Scientific Officer & Chief Medical Officer | 5.5yrs | AU$557.78k | 0.98% A$789.9k | |
| Company Secretary | 4.25yrs | no data | no data | |
| Director of Clinical Development & Regulatory Affairs | 3.67yrs | no data | no data | |
| Finance Director & Assistant Company Secretary | 2.42yrs | no data | no data |
4.0yrs
Average Tenure
46yo
Average Age
Experienced Management: IMM's management team is considered experienced (4 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, CFO | 5.92yrs | AU$836.83k | 1.57% A$1.3m | |
| Independent Non-Executive Chairman | 2.58yrs | AU$355.64k | 0.10% A$82.5k | |
| Independent Non-Executive Deputy Chairman | 2.58yrs | AU$60.93k | 0.31% A$247.6k | |
| Chairman of Clinical Advisory Board | 3yrs | no data | no data | |
| Independent Non-Executive Director | 2.83yrs | AU$127.18k | 0.27% A$214.7k | |
| Member of Clinical Advisory Board | 3yrs | no data | no data | |
| Member of Clinical Advisory Board | 3yrs | no data | no data | |
| Member of Clinical Advisory Board | 3yrs | no data | no data | |
| Member of Clinical Advisory Board | 3yrs | no data | no data |
3.0yrs
Average Tenure
48.5yo
Average Age
Experienced Board: IMM's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: IMM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 43.9%.
Top Shareholders
Company Information
Immutep Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Immutep Limited
- Ticker: IMM
- Exchange: ASX
- Founded:
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$80.459m
- Shares outstanding: 487.63m
- Website: https://www.immutep.com
Number of Employees
Location
- Immutep Limited
- 95 Pitt Street
- Level 12
- Sydney
- New South Wales
- 2000
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| IMM | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jan 1992 |
| PRRU.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Jan 1992 |
| YP1B | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jan 1992 |
| IMM | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jan 1992 |
| IMMP | NasdaqGM (Nasdaq Global Market) | SPONSORED ADS | US | USD | Apr 2012 | |
| YP1A | DB (Deutsche Boerse AG) | SPONSORED ADS | DE | EUR | Apr 2012 |
Biography
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company’s lead product candidate is eftilagimod alpha (efti), an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer. Its other products include TACTI-002, a combination of efti with KEYTRUDA that is in a Phase II clinical trial for solid tumors; INSIGHT-004, a human anti-PD-L1 antibody, which is in a Phase I clinical trial to evaluate a combination of efti with avelumab; and TACTI-mel that is in a Phase I clinical trial for metastatic melanoma. The company also develops IMP761 for autoimmune disease. It has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreements with Merck KGaA, Darmstadt, Germany, and Pfizer Inc.; and partnerships with GlaxoSmithKline, Novartis, CYTLIMIC, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/06/06 10:35 |
| End of Day Share Price | 2020/06/05 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.